MorphoSys AG: National Comprehensive Cancer Network Updates Designation of Monjuvi (tafasitamab-cxix) to Preferred Regimen in Its Clinical Practice Guidelines in Oncology for B-cell Lymphomas

BOSTON, MA / ACCESSWIRE / March 15, 2022 / MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG (FSE:MOR)(NASDAQ:MOR), announced today that the National Comprehensive Cancer Network(R) (NCCN)

Related Keywords

Germany ,Boston ,Massachusetts ,United States ,Planegg ,Bayern ,Thomas Biegi ,Julia Neugebauer ,Myles Clouston ,Jeanette Bressi ,Joe Horvat ,Practice Research Clinical Haematology ,Linkedin ,Xencor Inc ,Twitter ,Drug Administration ,Exchange Commission ,Morphosys Us Inc ,National Comprehensive Cancer Network ,National Comprehensive Cancer ,Clinical Practice Guidelines ,B Cell Lymphomas ,Preferred Regimen ,Diffuse Largeb Cell Lymphoma ,Diffuse Largeb Cell ,Antibody Dependent Cell Mediated Cytotoxicity ,Antibody Dependent Cellular Phagocytosis ,Medication Guide ,Prescribing Information ,Patient Information ,Important Safety ,Morphosy Annual Report ,Practice Research ,Morphosys ,Ational ,Comprehensive ,Dancer ,Network ,Updates ,Resignation ,Monjuvi ,Tafasitamab ,Wxix ,Referred ,Regimen ,Linical ,Practice ,Guidelines ,Ncology ,Fell ,Lymphomas ,